The authors (Miren Gaztañaga, MD, and Juanita Crook, MD, FRCPC) have disclosed that they have no financial interests, arrangements, commercial interest conflicts, or affiliations with the manufacturers of any products discussed in this article or their competitors.
Kerrin M. Green, MA, Assistant Managing Editor, Journal of the National Comprehensive Cancer Network.
Ms. Green has disclosed that she has no relevant financial relationships.
Nicole B. Fair, BS, Manager, Continuing Education and Grants
Ms. Fair has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations
Ms. Gregory has disclosed that she has no relevant financial relationships.
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;167(2 Pt 2):948–951; discussion 952.
Horwitz EM, Bae K, Hanks GE et al.. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497–2504.
Bolla M, Van Tienhoven G, Warde P et al.. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066–1073.
Roach M III, Bae K, Speight J et al.. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585–591.
Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981–989.
Mohler J, Bahnson RR, Boston B et al.. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162–200. To view the most recent version of these guidelines, visit NCCN.org.
Spry NA, Galvao DA, Davies R et al.. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int 2009;104:806–812.
Higano C, Shields A, Wood N et al.. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004;64:1182–1186.
Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448–4456.
Green HJ, Pakenham KI, Headley BC et al.. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002;90:427–432.
Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 2003;170:1808–1811.
D’Amico AV, Denham JW, Crook J et al.. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420–2425.
Alberti KG, Eckel RH, Grundy SM et al.. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–1645.
- Search Google Scholar
- Export Citation
. Alberti KG Eckel RH Grundy SM Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640– 1645.
Tsai HK, D’Amico AV, Sadetsky N et al.. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516–1524.
Nguyen PL, Je Y, Schutz FA et al.. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306:2359–2366.
Jones CU, Hunt D, McGowan DG et al.. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107–118.
Lu-Yao GL, Albertsen PC, Moore DF et al.. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173–181.
Sanda MG, Dunn RL, Michalski J et al.. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–1261.
Beyer DC, McKeough T, Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005;61:1299–1305.
D’Amico AV, Manola J, Loffredo M et al.. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821–827.
Zelefsky MJ, Reuter VE, Fuks Z et al.. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 2008;179:1368–1373; discussion 1373.
Kuban DA, Tucker SL, Dong L et al.. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.
Zietman AL, DeSilvio ML, Slater JD et al.. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233–1239.
Peeters ST, Heemsbergen WD, Koper PC et al.. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990–1996.
Deutsch I, Zelefsky MJ, Zhang Z et al.. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 2010;9:313–318.
Stock RG, Yalamanchi S, Hall SJ, Stone NN. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. J Urol 2010;183:546–550.
Valicenti RK, Bae K, Michalski J et al.. Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. Int J Radiat Oncol Biol Phys 2011;79:1323–1329.
Martinez AA, Demanes DJ, Galalae R et al.. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys 2005;62:1322–1331.
Pilepich MV, Winter K, Lawton CA et al.. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285–1290.
D’Amico AV, Moul JW, Carroll PR et al.. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst 2004;96:509–515.
Denham JW, Steigler A, Lamb DS et al.. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841–850.
Stock RG, Ho A, Cesaretti JA, Stone NN. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 2006;66:389–394.
Loblaw DA, Virgo KS, Nam R et al.. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596–1605.
Pound CR, Partin AW, Eisenberger MA et al.. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–1597.
D’Amico AV, Kantoff P, Loffredo M et al.. Predictors of mortality after prostate-specific antigen failure. Int J Radiat Oncol Biol Phys 2006;65:656–660.
Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58:2546–2550.
Bruchovsky N, Rennie PS, Coldman AJ et al.. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50:2275–2282.
Sato N, Gleave ME, Bruchovsky N et al.. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996;58:139–146.
Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years’ follow-up. Mol Urol 1999;3:287–292.
Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996;48:800–804.
Malone S, Perry G, Eapen L et al.. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome. Int J Radiat Oncol Biol Phys 2007;68:699–706.
Bouchot O, Lenormand L, Karam G et al.. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000;38:543–549.
Crook JM, Malone S, Horwitz E et al.. A phase III randomized trial of intermittent vs. continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013) [abstract]. J Clin Oncol 2011; 29(Suppl):Abstract 4514.
- Search Google Scholar
- Export Citation
. Crook JM Malone S Horwitz E A phase III randomized trial of intermittent vs. continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013) [abstract]. J Clin Oncol 2011; 29( Suppl): Abstract 4514.
Hussain M, Tangen CM, Higano CS et al.. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 4.
- Search Google Scholar
- Export Citation
. Hussain M Tangen CM Higano CS Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial [abstract]. J Clin Oncol 2012; 30( Suppl): Abstract 4.
Lebret T, Coloby P, Descotes JL et al.. Educational tool-kit on diet and exercise: survey of prostate cancer patients about to receive androgen deprivation therapy. Urology 2010;76:1434–1439.
Moyad MA. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol 2005;23:56–64.
Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003;61(2 Suppl 1):32–38.
Nobes JP, Langley SE, Klopper T et al.. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2011;109:1495–1502.
Segal RJ, Reid RD, Courneya KS et al.. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009;27:344–351.
Alibhai SM, Breunis H, Timilshina N et al.. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol 2010;28:5030–5037.
Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146:416–424.
Michaelson MD, Kaufman DS, Lee H et al.. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:1038–1042.
Smith MR, Eastham J, Gleason DM et al.. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008–2012.
Smith MR, Egerdie B, Hernandez Toriz N et al.. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745–755.
Stock RG, Cesaretti JA, Hall SJ, Stone NN. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 2009;104:1631–1636.
Bolla M, de Reijke TM, Van Tienhoven G et al.. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–2527.